Standard BioTools (LAB) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

LAB Stock Forecast

Standard BioTools stock forecast is as follows: an average price target of $3.25 (represents a 62.50% upside from LAB’s last price of $2.00) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

LAB Price Target

The average price target for Standard BioTools (LAB) is $3.25 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $3.25 to $3.25. This represents a potential 62.50% upside from LAB's last price of $2.00.

LAB Analyst Ratings

Buy

According to 3 Wall Street analysts, Standard BioTools's rating consensus is 'Buy'. The analyst rating breakdown for LAB stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Standard BioTools Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 04, 2024	Matthew Stanton	Jefferies	$3.25	$2.66	22.18%	62.50%

The latest Standard BioTools stock forecast, released on Apr 04, 2024 by Matthew Stanton from Jefferies, set a price target of $3.25, which represents a 22.18% increase from the stock price at the time of the forecast ($2.66), and a 62.50% increase from LAB last price ($2.00).

Standard BioTools Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$3.25
Last Closing Price	$2.00	$2.00	$2.00
Upside/Downside	-100.00%	-100.00%	62.50%

In the current month, the average price target of Standard BioTools stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Standard BioTools's last price of $2.00. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 16, 2024	Cowen & Co.	Buy	Buy	Hold
Apr 16, 2024	Cowen & Co.		Buy	Initialise
Apr 04, 2024	Jefferies		Buy	Initialise
Jul 12, 2023	KeyBanc		Overweight	Initialise

Standard BioTools's last stock rating was published by Cowen & Co. on Sep 16, 2024. The company gave LAB a "Buy" rating, the same as its previous rate.

Standard BioTools Financial Forecast

Standard BioTools Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	-	-	-	-	-	-	-	-	$28.19M	$25.37M	$27.67M	$25.12M	$27.02M	$25.65M	$18.78M	$26.50M	$38.27M	$28.50M	$31.02M	$32.79M	$44.61M	$39.86M	$26.06M	$27.62M	$32.44M	$26.50M	$28.20M	$30.11M
Avg Forecast	$48.55M	$48.65M	$41.90M	$45.60M	$43.03M	$41.00M	$48.25M	$46.01M	$24.90M	$23.60M	$24.20M	$28.36M	$38.00M	$30.95M	$29.78M	$25.65M	$32.67M	$30.00M	$30.99M	$32.39M	$50.70M	$32.47M	$19.07M	$29.05M	$30.94M	$28.74M	$30.16M	$29.20M
High Forecast	$49.99M	$50.10M	$43.15M	$46.96M	$44.22M	$41.15M	$48.25M	$46.01M	$25.64M	$24.30M	$24.92M	$29.20M	$39.13M	$30.95M	$29.78M	$25.65M	$32.67M	$30.00M	$30.99M	$32.39M	$50.70M	$32.47M	$19.07M	$29.05M	$30.94M	$28.74M	$30.16M	$29.20M
Low Forecast	$47.37M	$47.46M	$40.88M	$44.49M	$41.84M	$40.85M	$48.25M	$46.01M	$24.29M	$23.02M	$23.61M	$27.67M	$37.07M	$30.95M	$29.78M	$25.65M	$32.67M	$30.00M	$30.99M	$32.39M	$50.70M	$32.47M	$19.07M	$29.05M	$30.94M	$28.74M	$30.16M	$29.20M
# Analysts	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	1.13%	1.07%	1.14%	0.89%	0.71%	0.83%	0.63%	1.03%	1.17%	0.95%	1.00%	1.01%	0.88%	1.23%	1.37%	0.95%	1.05%	0.92%	0.93%	1.03%

Standard BioTools's average Quarter revenue forecast for Mar 24 based on 1 analysts is $46.01M, with a low forecast of $46.01M, and a high forecast of $46.01M. LAB's average Quarter revenue forecast represents a 63.21% increase compared to the company's last Quarter revenue of $28.19M (Dec 23).

Standard BioTools EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	$-21.39M	$-21.17M	$-17.45M	$-11.80M	$-15.97M	$-25.49M	$-37.97M	$-23.41M	$-5.29M	$-10.43M	$-12.87M	$-15.69M	$-12.14M	$-1.39M	$-9.37M	$-11.70M	$-4.75M	$-9.68M	$-10.45M	$-9.73M
Avg Forecast	$-24.23M	$-24.28M	$-20.91M	$-22.76M	$-21.48M	$-20.46M	$-24.08M	$-22.96M	$-12.43M	$-11.78M	$-12.08M	$-14.15M	$-18.97M	$-14.45M	$-13.90M	$-11.98M	$-15.26M	$-14.01M	$-14.47M	$-15.12M	$-23.67M	$-15.16M	$-8.90M	$-13.56M	$-14.45M	$-13.42M	$-14.08M	$-13.63M
High Forecast	$-23.64M	$-23.69M	$-20.40M	$-22.20M	$-20.88M	$-20.39M	$-24.08M	$-22.96M	$-12.12M	$-11.49M	$-11.78M	$-13.81M	$-18.50M	$-14.45M	$-13.90M	$-11.98M	$-15.26M	$-14.01M	$-14.47M	$-15.12M	$-23.67M	$-15.16M	$-8.90M	$-13.56M	$-14.45M	$-13.42M	$-14.08M	$-13.63M
Low Forecast	$-24.95M	$-25.00M	$-21.53M	$-23.44M	$-22.07M	$-20.54M	$-24.08M	$-22.96M	$-12.80M	$-12.13M	$-12.44M	$-14.58M	$-19.53M	$-14.45M	$-13.90M	$-11.98M	$-15.26M	$-14.01M	$-14.47M	$-15.12M	$-23.67M	$-15.16M	$-8.90M	$-13.56M	$-14.45M	$-13.42M	$-14.08M	$-13.63M
Surprise %	-	-	-	-	-	-	-	-	1.72%	1.80%	1.44%	0.83%	0.84%	1.76%	2.73%	1.95%	0.35%	0.74%	0.89%	1.04%	0.51%	0.09%	1.05%	0.86%	0.33%	0.72%	0.74%	0.71%

undefined analysts predict LAB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Standard BioTools's previous annual EBITDA (undefined) of $NaN.

Standard BioTools Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	$-19.78M	$-21.00M	$-17.04M	$-16.84M	$-20.84M	$-29.43M	$-63.54M	$-76.29M	$-9.43M	$-13.84M	$-17.14M	$-18.82M	$-18.03M	$-6.00M	$-13.02M	$-15.98M	$-12.69M	$-12.89M	$-13.75M	$-25.46M
Avg Forecast	$-11.15M	$-16.72M	$-14.86M	$-20.43M	$-21.05M	$-33.44M	$-30.96M	$-41.75M	$-89.17M	$-85.45M	$-78.02M	$-20.56M	$-40.87M	$-48.40M	$-48.40M	$-55.85M	$-104.25M	$-81.91M	$-72.60M	$-69.74M	$-24.39M	$-74.52M	$-85.68M	$-71.09M	$-70.74M	$-74.87M	$-77.40M	$-93.56M
High Forecast	$-10.79M	$-16.19M	$-14.39M	$-19.79M	$-20.39M	$-32.38M	$-29.98M	$-40.43M	$-86.34M	$-82.75M	$-75.55M	$-19.91M	$-39.57M	$-48.40M	$-48.40M	$-55.85M	$-104.25M	$-81.91M	$-72.60M	$-69.74M	$-24.39M	$-74.52M	$-85.68M	$-71.09M	$-70.74M	$-74.87M	$-77.40M	$-93.56M
Low Forecast	$-11.58M	$-17.37M	$-15.44M	$-21.22M	$-21.87M	$-34.73M	$-32.16M	$-43.37M	$-92.62M	$-88.76M	$-81.04M	$-21.36M	$-42.45M	$-48.40M	$-48.40M	$-55.85M	$-104.25M	$-81.91M	$-72.60M	$-69.74M	$-24.39M	$-74.52M	$-85.68M	$-71.09M	$-70.74M	$-74.87M	$-77.40M	$-93.56M
Surprise %	-	-	-	-	-	-	-	-	0.22%	0.25%	0.22%	0.82%	0.51%	0.61%	1.31%	1.37%	0.09%	0.17%	0.24%	0.27%	0.74%	0.08%	0.15%	0.22%	0.18%	0.17%	0.18%	0.27%

Standard BioTools's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LAB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Standard BioTools SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	$21.35M	$22.29M	$22.60M	$22.31M	$23.90M	$29.60M	$30.38M	$30.88M	$22.96M	$24.07M	$24.25M	$27.61M	$31.93M	$22.66M	$20.62M	$22.70M	$18.79M	$20.73M	$22.13M	$22.82M
Avg Forecast	$40.60M	$40.68M	$35.04M	$38.13M	$35.99M	$34.29M	$40.35M	$38.47M	$20.82M	$19.74M	$20.24M	$23.72M	$31.78M	$25.88M	$24.90M	$21.45M	$27.32M	$25.09M	$25.92M	$27.08M	$42.40M	$27.16M	$15.95M	$24.29M	$25.87M	$24.03M	$25.22M	$24.42M
High Forecast	$41.81M	$41.89M	$36.08M	$39.27M	$36.98M	$34.41M	$40.35M	$38.47M	$21.44M	$20.32M	$20.84M	$24.42M	$32.72M	$25.88M	$24.90M	$21.45M	$27.32M	$25.09M	$25.92M	$27.08M	$42.40M	$27.16M	$15.95M	$24.29M	$25.87M	$24.03M	$25.22M	$24.42M
Low Forecast	$39.61M	$39.69M	$34.19M	$37.20M	$34.99M	$34.16M	$40.35M	$38.47M	$20.32M	$19.25M	$19.74M	$23.14M	$31.00M	$25.88M	$24.90M	$21.45M	$27.32M	$25.09M	$25.92M	$27.08M	$42.40M	$27.16M	$15.95M	$24.29M	$25.87M	$24.03M	$25.22M	$24.42M
Surprise %	-	-	-	-	-	-	-	-	1.03%	1.13%	1.12%	0.94%	0.75%	1.14%	1.22%	1.44%	0.84%	0.96%	0.94%	1.02%	0.75%	0.83%	1.29%	0.93%	0.73%	0.86%	0.88%	0.93%

Standard BioTools's average Quarter SG&A projection for Mar 24 is $38.47M, based on 1 Wall Street analysts, with a range of $38.47M to $38.47M. The forecast indicates a 80.17% rise compared to LAB last annual SG&A of $21.35M (Dec 23).

Standard BioTools EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	$-0.25	$-0.27	$-0.22	$-0.21	$-0.26	$-0.37	$-0.82	$-0.99	$-0.12	$-0.18	$-0.23	$-0.25	$-0.24	$-0.08	$-0.18	$-0.23	$-0.18	$-0.19	$-0.20	$-0.44
Avg Forecast	$-0.03	$-0.04	$-0.04	$-0.06	$-0.06	$-0.09	$-0.08	$-0.11	$-0.24	$-0.23	$-0.21	$-0.06	$-0.11	$-0.13	$-0.13	$-0.15	$-0.28	$-0.22	$-0.20	$-0.19	$-0.07	$-0.20	$-0.23	$-0.19	$-0.19	$-0.20	$-0.21	$-0.25
High Forecast	$-0.03	$-0.04	$-0.04	$-0.05	$-0.05	$-0.09	$-0.08	$-0.11	$-0.23	$-0.22	$-0.20	$-0.05	$-0.11	$-0.13	$-0.13	$-0.15	$-0.28	$-0.22	$-0.20	$-0.19	$-0.07	$-0.20	$-0.23	$-0.19	$-0.19	$-0.20	$-0.21	$-0.25
Low Forecast	$-0.03	$-0.05	$-0.04	$-0.06	$-0.06	$-0.09	$-0.09	$-0.12	$-0.25	$-0.24	$-0.22	$-0.06	$-0.11	$-0.13	$-0.13	$-0.15	$-0.28	$-0.22	$-0.20	$-0.19	$-0.07	$-0.20	$-0.23	$-0.19	$-0.19	$-0.20	$-0.21	$-0.25
Surprise %	-	-	-	-	-	-	-	-	1.04%	1.17%	1.05%	3.79%	2.36%	2.85%	6.31%	6.60%	0.43%	0.82%	1.18%	1.33%	3.66%	0.41%	0.78%	1.20%	0.95%	0.94%	0.96%	1.75%

According to undefined Wall Street analysts, Standard BioTools's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LAB previous annual EPS of $NaN (undefined).

Standard BioTools Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
DRIO	DarioHealth	$0.71	$10.75	1414.08%	Buy
MDXH	MDxHealth SA	$2.37	$15.00	532.91%	Buy
STIM	Neuronetics	$1.30	$8.00	515.38%	Buy
BDSX	Biodesix	$1.39	$3.00	115.83%	Buy
LAB	Standard BioTools	$2.21	$3.25	47.06%	Buy
NDRA	ENDRA Life Sciences	$4.58	$5.00	9.17%	Buy
NOTV	Inotiv	$5.55	$6.00	8.11%	Buy

LAB Forecast FAQ

Is Standard BioTools a good buy?

Yes, according to 3 Wall Street analysts, Standard BioTools (LAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of LAB's total ratings.

What is LAB's price target?

Standard BioTools (LAB) average price target is $3.25 with a range of $3.25 to $3.25, implying a 62.50% from its last price of $2. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Standard BioTools stock go up soon?

According to Wall Street analysts' prediction for LAB stock, the company can go up by 62.50% (from the last price of $2 to the average price target of $3.25), up by 62.50% based on the highest stock price target, and up by 62.50% based on the lowest stock price target.

Can Standard BioTools stock reach $3?

LAB's average twelve months analyst stock price target of $3.25 supports the claim that Standard BioTools can reach $3 in the near future.

What are Standard BioTools's analysts' financial forecasts?

Standard BioTools's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $178.29M (high $179.63M, low $176.95M), average EBITDA is $-88.981M (high $-88.312M, low $-89.649M), average net income is $-127M (high $-123M, low $-132M), average SG&A $149.1M (high $150.22M, low $147.98M), and average EPS is $-0.342 (high $-0.332, low $-0.356). LAB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $184.7M (high $190.19M, low $180.2M), average EBITDA is $-92.181M (high $-89.934M, low $-94.923M), average net income is $-63.161M (high $-61.16M, low $-65.604M), average SG&A $154.46M (high $159.05M, low $150.69M), and average EPS is $-0.17 (high $-0.165, low $-0.177).

Did the LAB's actual financial results beat the analysts' financial forecasts?

Based on Standard BioTools's last annual report (Dec 2023), the company's revenue was $106.34M, beating the average analysts forecast of $101.06M by 5.22%. Apple's EBITDA was $-76.6M, beating the average prediction of $-50.438M by 51.87%. The company's net income was $-74.656M, missing the average estimation of $-273M by -72.67%. Apple's SG&A was $87.54M, beating the average forecast of $84.51M by 3.58%. Lastly, the company's EPS was $-0.94, beating the average prediction of $-0.735 by 27.83%. In terms of the last quarterly report (Dec 2023), Standard BioTools's revenue was $28.19M, beating the average analysts' forecast of $24.9M by 13.20%. The company's EBITDA was $-21.386M, beating the average prediction of $-12.427M by 72.09%. Standard BioTools's net income was $-19.776M, missing the average estimation of $-89.169M by -77.82%. The company's SG&A was $21.35M, beating the average forecast of $20.82M by 2.55%. Lastly, the company's EPS was $-0.25, beating the average prediction of $-0.24 by 4.17%